Aytu Biopharma (AYTU) Cash & Current Investments (2011 - 2026)

Aytu Biopharma (AYTU) has reported Cash & Current Investments for 16 consecutive years, with $26.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 47.0% year-over-year to $26.7 million in Q1 2026; TTM through Mar 2026 was $26.7 million, a 47.0% increase from a year earlier, with the FY2025 full-year figure at $31.0 million, up 54.71% from the prior year.
• Cash & Current Investments was $26.7 million for Q1 2026 at Aytu Biopharma, down from $30.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $32.6 million in Q3 2025 and troughed at $18.2 million in Q1 2025.
• A 5-year average of $23.0 million and a median of $20.1 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 61.4% in 2022 and soared 62.27% in 2025, its largest moves.
• Over 5 years, Cash & Current Investments stood at $19.5 million in 2022, then gained by 0.14% to $19.5 million in 2023, then gained by 4.45% to $20.4 million in 2024, then surged by 47.2% to $30.0 million in 2025, then fell by 11.02% to $26.7 million in 2026.
• The last three Cash & Current Investments figures came in at $26.7 million (Q1 2026), $30.0 million (Q4 2025), and $32.6 million (Q3 2025), per Business Quant data.